Enliven Therapeutics (NASDAQ:ELVN) & Aptorum Group (NASDAQ:APM) Critical Survey

Enliven Therapeutics (NASDAQ:ELVN) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Institutional and Insider Ownership

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by insiders. Comparatively, 64.0% of Aptorum Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Enliven Therapeutics and Aptorum Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1	0	5	0	2.67
Aptorum Group	1	0	0	0	1.00

Enliven Therapeutics currently has a consensus price target of $41.20, suggesting a potential upside of 133.69%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Enliven Therapeutics is more favorable than Aptorum Group.

Profitability

This table compares Enliven Therapeutics and Aptorum Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-29.15%	-27.88%
Aptorum Group	N/A	N/A	N/A

Valuation & Earnings

This table compares Enliven Therapeutics and Aptorum Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$89.02 million	($2.00)	-8.82
Aptorum Group	$430,000.00	17.17	-$4.27 million	N/A	N/A

Aptorum Group has higher revenue and earnings than Enliven Therapeutics.

Risk & Volatility

Enliven Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.